U.S. Residential REITs Stock News

Nvidia’s move to secure US$500b for AI data centres has turned compute infrastructure into a headline asset class and put global alternative asset managers firmly in the spotlight. Capital is flowing toward firms that can source, structure, and deploy money into this AI build out. This article looks at 3 stocks from our Global Alternative Asset Managers screener that are closely linked to this trend and explains why their AI exposure may be relevant for investors. The stocks covered below are...

CareDx (CDNA) has drawn fresh attention after reporting second quarter 2026 results, moving from a prior net loss to net income of $110.64 million, alongside higher year over year revenue and raised full year guidance. See our latest analysis for CareDx. The latest earnings announcement and raised 2026 guidance have come alongside a sharp shift in sentiment toward CareDx, with a 30 day share price return of 65.10% and a year to date share price return of 145.92%. Over a longer horizon, the 1...

Kaspi.kz has reported its second-quarter 2026 results, with revenue rising to KZT 1,112,152 million and net income holding roughly flat at KZT 258,889 million compared with a year earlier, alongside first-half revenue of KZT 2,192,782 million and net income of KZT 510,796 million. At the same time, the company proposed lifting its quarterly dividend by 18% to KZT 1,000 per ADS, signalling that management is willing to return more cash to shareholders even as earnings remain broadly unchanged...

Dividend and earnings announcement put Del Monte in focus Del Monte (DMC) drew fresh attention after reporting second quarter and half year results that showed lower profitability alongside relatively steady sales, while also declaring a quarterly dividend of $0.30 per share. See our latest analysis for Del Monte. The earnings release and dividend decision appear to be landing in a mixed sentiment period for Del Monte, with the share price up 6.96% over 30 days but down 14.68% over 90 days...

In the second quarter of 2026, Green Plains Inc. reported sales of US$446.22 million, net income of US$67.15 million and diluted earnings per share from continuing operations of US$0.83, alongside lower ethanol and coproduct production versus a year earlier. The shift from a loss to profit despite reduced volumes suggests that cost management and operational efficiencies had a meaningful effect on Green Plains’ profitability profile in the period. We’ll now examine how this profitability...

In recent weeks, Brown-Forman has attracted renewed investor attention as analysts highlight mixed valuation signals, with cash-flow-based models implying the shares may be trading below intrinsic value while earnings multiples point closer to fair value. This tension between perceived undervaluation and ongoing pressure from softer spirits demand and higher input costs is increasingly shaping how investors assess Brown-Forman’s long-term prospects. Next, we’ll examine how this focus on...

Why Monster Beverage Stock Is Back in Focus After Q2 2026 Results Monster Beverage (MNST) has drawn fresh attention after reporting its second quarter 2026 results on 6 August, with higher sales and net income, as well as active discussion of its international revenue mix. See our latest analysis for Monster Beverage. Monster Beverage shares trade at US$91.43 after the latest results, with a 90 day share price return of 6.47% and a year to date share price return of 20.05%. The 1 year total...

eBay stock has delivered a very strong 157.8% return over the past three years, yet current valuation checks send a mixed message, with a Discounted Cash Flow (DCF) estimate pointing to meaningful upside while market based multiples look closer to fairly priced. Over the last three years, eBay has returned 157.8%, which puts extra focus on whether today’s price still leaves enough room above intrinsic value. Recent growth in luxury resale, collectibles and apparel, helped by AI powered...

PTC Therapeutics (PTCT) reported second quarter 2026 results that shifted from a loss a year ago to net income of US$83.5 million, along with higher full year revenue guidance of US$1.18b to US$1.28b. See our latest analysis for PTC Therapeutics. The latest earnings update and raised revenue guidance appear to have shifted sentiment around PTC Therapeutics. The share price is up 9.56% over the past week but down 12.04% over the past month, while a 72.36% 1 year total shareholder return points...

Sociedad Química y Minera de Chile S.A. and Wesfarmers have approved expanding the Mt Holland lithium project in Australia, aiming to double annual spodumene concentrate output to about 760,000 tonnes and add a new ore sorting facility, with SQM expecting to invest roughly US$450 million to US$500 million. The expansion gives SQM more flexibility to either feed any future increase in downstream processing at the Kwinana refinery or sell higher volumes of concentrate directly into the lithium...

AI related spending now accounts for a large share of US$1.5 trillion in expected S&P 500 capex and corporate earnings are reported up 32%, which helps explain why JPMorgan recently lifted its S&P 500 target to 8,000. That kind of backdrop can quickly reward or punish companies exposed to this surge. This article walks through three US stocks from our earnings growth screener that appear tightly linked to these trends. The three stocks below are just a starting sample from this earnings...

With the Iran conflict straining global oil flows and the Jones Act waiver reshaping how fuel moves between U.S. ports, domestic infrastructure and logistics stocks suddenly sit closer to the action than many investors expected. Supply chains are being rerouted, costs are shifting and some companies could see fresh demand while others face new pressure. This article spotlights 3 stocks exposed to these crosscurrents and explains what their roles might mean for your portfolio. The three...

Recent board changes at Uranium Royalty (NasdaqCM:UROY) have put governance in focus after a busy few weeks that also included fresh annual results, a new shelf registration, and a voluntary SEC deregistration. See our latest analysis for Uranium Royalty. Against this backdrop of board changes, annual results and new capital plans, Uranium Royalty’s share price has moved sharply in recent weeks, with a 30 day share price return of 50.18% and a 1 year total shareholder return of 60.70%, which...

Tilley Harley-Davidson previously hosted its Freedom Revival, a 1970s-themed classic motorcycle show at its Statesville, North Carolina dealership, showcasing vintage Shovelhead and Ironhead models alongside highlighted pre-owned CVO Street Glide bikes. At the same time, Harley-Davidson’s relatively low motorcycle sales and weak free cash flow margin have drawn attention to underlying operational and financial strains. We’ll now examine how softer core motorcycle demand, and the resulting...

UroGen Pharma’s recently reported Q2 2026 results showed sales rising to US$72.46 million from US$24.22 million a year earlier, while net loss narrowed to US$14.35 million and basic loss per share improved to US$0.28. Across the first half of 2026, the company almost tripled sales to US$123.42 million and roughly halved its net loss, pointing to emerging operating leverage as revenue scales despite continued losses. We’ll now examine how this sharp revenue growth and narrowed loss profile...

Equity offering and shelf registration reshape the picture for Xenia Hotels & Resorts stock Xenia Hotels & Resorts (XHR) has just completed a US$136.9 million at the market common stock offering and filed a new US$200 million shelf registration. This provides the company with fresh funding capacity that investors will likely watch closely. See our latest analysis for Xenia Hotels & Resorts. Despite a recent pullback, with a 7 day share price return of down 7.9% and a 30 day share price return...

Ingevity Corporation reported past second-quarter 2026 results with sales of US$314.1 million, net income of US$35.3 million, and diluted earnings per share from continuing operations of US$1.13, alongside ongoing progress on portfolio reshaping and a completed share repurchase of 493,375 shares for US$35 million under its 2022 buyback program. The shift from a prior-year loss to profitability, combined with higher full-year adjusted EBITDA and EPS guidance, highlights management’s...

Vistance Networks (VISN) has drawn fresh attention after reporting second quarter earnings along with a special $5.00 per share cash distribution, a combination that puts both recent profit trends and capital returns in focus for shareholders. See our latest analysis for Vistance Networks. Alongside the stronger earnings and the special distribution, Vistance Networks has seen mixed share price momentum, with the share price down 37.46% year to date but a very large 3 year total shareholder...

Universal Technical Institute (UTI) is back in focus after its latest earnings update, which combined higher third quarter revenue and new student starts with a reduced fiscal 2026 outlook tied to enrollment mix and guidance revisions. See our latest analysis for Universal Technical Institute. The earnings update and lowered fiscal 2026 guidance have clearly shifted sentiment, with Universal Technical Institute’s share price falling 35.33% over the past week and 44.85% over the past month,...

With fresh tariffs on 60 key U.S. trading partners drawing a hard line on forced labor, the spotlight has swung to companies that rely more on domestic supply chains than global ones. This shift could reshape where risks and potential opportunities sit in your portfolio, especially as costs and inflation pressures ripple through. This article walks through three U.S.-focused stocks exposed to the tariff story and explains why they may warrant closer attention now. The three stocks covered...

Why Bank of New York Mellon Corporation Stock Is Back in Focus Bank of New York Mellon Corporation (BNY) is back on investors’ radar after fresh moves in digital assets, including a new staking partnership with Galaxy Digital and the rollout of tokenized fund and transfer agency capabilities. See our latest analysis for Bank of New York Mellon. Alongside these digital asset moves, the BNY share price has been firm, with a 1-month share price return of 4.94% and a 90-day share price return of...

MoonLake Immunotherapeutics reported second-quarter 2026 results, posting a net loss of US$61.81 million (US$0.84 basic loss per share) and announcing that its Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve adults with active psoriatic arthritis met all clinical endpoints at Week 16. The trial’s topline data showed clinically meaningful improvements across joint, skin and quality-of-life measures, reinforcing sonelokimab’s potential to address multiple manifestations of psoriatic...

In late July 2026, Antero Resources Corporation reported higher second-quarter 2026 revenue of US$1,559.84 million and net income of US$278.66 million, alongside record production and lower impairments compared with the prior year. The company also raised its full-year 2026 production guidance and continued its share repurchase program, signaling management confidence backed by stronger operating performance and recent acquisitions. We’ll now examine how Antero’s upgraded 2026 production...

ICU Medical (ICUI) raised its 2026 earnings guidance after releasing second quarter results on 6 August 2026, indicating higher expected GAAP net income and diluted EPS for the full year. See our latest analysis for ICU Medical. ICU Medical’s latest guidance hike comes after a strong run in the stock, with a 30 day share price return of 18.13% and a 1 year total shareholder return of 68.75%. This suggests momentum has been building as investors reassess growth potential and risk. If this kind...